US Stock Market Move | Orforglipron's oral weight-loss drug program achieves success in Phase III trial, causing Eli Lilly (LLY.US) stock to rise more than 3%.

On Thursday, the stock price of Eli Lilly (LLY.US) rose by more than 3% at one point. At the time of writing, the stock had narrowed its gain to 1.84%, trading at $1061. The company announced that its oral weight-loss drug orforglipron showed superior weight maintenance effects compared to the control group in a Phase III clinical trial, suitable for obese or overweight adults who have previously used injectable weight-loss drugs (including the company's own Zepbound and Novo Nordisk A/S Sponsored ADR Class B (NVO.US)'s Wegovy). Eli Lilly cited top-line data from the ATTAIN-MAINTAIN trial, stating that in a 52-week study, patients transitioning from Wegovy or Zepbound to orforglipron were able to maintain the weight loss achieved through injectable drugs. Data showed that compared to the control, patients who switched from Wegovy had an average weight difference of 0.9 kilograms, while those who switched from Zepbound had an average weight difference of 5.0 kilograms. The company stated that the study met its primary endpoint and all key secondary endpoints. In terms of safety and tolerability, the performance of orforglipron was consistent with previous Phase III study results, demonstrating the safety profile of once-daily oral dosing.